05Y.F VIVORYON THERAPEUTICS

Healthcare Biotechnology Frankfurt Exchange
0.7600 EUR
Close of Nov 11, 2026
0.5560 1.64
Market cap
EUR 22.5M
P/E
-
P/B
12.72x
ROE
-187.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 05Y.F undervalued?

Graham number

The Graham number of VIVORYON THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VIVORYON THERAPEUTICS fundamental analysis

No fundamental analysis for VIVORYON THERAPEUTICS yet.

VIVORYON THERAPEUTICS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VIVORYON THERAPEUTICS

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company i…

Full company profile